Skip to main content

OGT Licenses Patents to Biotype Diagnostics for Microarray Technology Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Gene Technology today announced it has licensed its patents for detecting DNA sequence variations to Biotype Diagnostics, which will use it to develop a microarray platform.

The rights are valid for the lifetime of the patents and give Biotype certain rights with respect to SNP genotyping, OGT said in a statement. Financial and other terms of the deal were not disclosed.

Wilhelm Zorgiebel, executive director for Dresden, Germany-based Biotype, said that the agreement "helps us to develop our own microarray technology platform for various applications in medicine and analytics."

He added that the firm intends to develop a microarray kit for simultaneous analysis of the 27 most important wood-rotting fungi in Europe.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.